Zia Valda

ZiaValda is an early-stage biotechnology company focused on the development of oncolytic virus therapies for the treatment of aggressive brain cancers, specifically glioblastoma multiforme (GBM). The company's platform utilizes a proprietary, live-attenuated Zika virus (ZIKV) that exploits the virus's natural neurotropism to selectively infect and eliminate glioblastoma stem cells. This approach aims to overcome the high resistance and recurrence rates associated with standard GBM treatments by targeting the root of tumor growth. ZiaValda's lead program is currently in the preclinical stage, with ongoing research supported by the University of Texas Medical Branch (UTMB). The company represents a novel application of virology to oncology, turning a known pathogen into a therapeutic tool.